Lepu Medical Technology (Beijing) Toekomstige groei
Future criteriumcontroles 4/6
Lepu Medical Technology (Beijing) zal naar verwachting groeien in winst en omzet met respectievelijk 42.4% en 19.4% per jaar. De winst per aandeel zal naar verwachting groeien met 41.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 9.6% zijn.
Belangrijke informatie
42.4%
Groei van de winst
41.9%
Groei van de winst per aandeel
Medical Equipment winstgroei | 27.5% |
Inkomstengroei | 19.4% |
Toekomstig rendement op eigen vermogen | 9.6% |
Dekking van analisten | Good |
Laatst bijgewerkt | 29 Oct 2024 |
Recente toekomstige groei-updates
Lepu Medical Technology (Beijing) Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 28Earnings Miss: Lepu Medical Technology (Beijing) Co., Ltd. Missed EPS By 56% And Analysts Are Revising Their Forecasts
Aug 27Recent updates
Lepu Medical Technology (Beijing) Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 28Investors Still Aren't Entirely Convinced By Lepu Medical Technology (Beijing) Co., Ltd.'s (SZSE:300003) Earnings Despite 33% Price Jump
Oct 18Investors Give Lepu Medical Technology (Beijing) Co., Ltd. (SZSE:300003) Shares A 26% Hiding
Sep 02News Flash: 7 Analysts Think Lepu Medical Technology (Beijing) Co., Ltd. (SZSE:300003) Earnings Are Under Threat
Aug 31Earnings Miss: Lepu Medical Technology (Beijing) Co., Ltd. Missed EPS By 56% And Analysts Are Revising Their Forecasts
Aug 27Lepu Medical Technology (Beijing) (SZSE:300003) Might Be Having Difficulty Using Its Capital Effectively
Aug 16Lepu Medical Technology (Beijing)'s (SZSE:300003) Dividend Is Being Reduced To CN¥0.3314
Jun 23Lepu Medical Technology (Beijing) (SZSE:300003) Seems To Use Debt Quite Sensibly
May 31Capital Allocation Trends At Lepu Medical Technology (Beijing) (SZSE:300003) Aren't Ideal
May 13Lepu Medical Technology (Beijing) (SZSE:300003) Has A Pretty Healthy Balance Sheet
Feb 28Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 9,729 | 1,951 | N/A | 2,548 | 7 |
12/31/2025 | 8,405 | 1,632 | N/A | 2,078 | 8 |
12/31/2024 | 6,422 | 980 | N/A | 2,112 | 4 |
9/30/2024 | 6,506 | 707 | 159 | 810 | N/A |
6/30/2024 | 7,062 | 994 | 303 | 1,008 | N/A |
3/31/2024 | 7,465 | 1,143 | 488 | 1,266 | N/A |
12/31/2023 | 7,980 | 1,258 | 146 | 990 | N/A |
9/30/2023 | 9,107 | 1,747 | 642 | 1,573 | N/A |
6/30/2023 | 9,577 | 1,897 | 794 | 1,754 | N/A |
3/31/2023 | 10,498 | 2,254 | 1,320 | 2,208 | N/A |
12/31/2022 | 10,609 | 2,204 | 1,885 | 2,791 | N/A |
9/30/2022 | 9,787 | 1,608 | 1,611 | 2,558 | N/A |
6/30/2022 | 9,473 | 1,262 | 1,118 | 2,106 | N/A |
3/31/2022 | 10,460 | 1,539 | 1,211 | 2,212 | N/A |
1/1/2022 | 10,660 | 1,719 | 2,078 | 3,062 | N/A |
9/30/2021 | 10,286 | 1,750 | 1,954 | 2,812 | N/A |
6/30/2021 | 10,321 | 2,387 | 2,269 | 3,086 | N/A |
3/31/2021 | 9,121 | 2,144 | 2,567 | 3,284 | N/A |
12/31/2020 | 8,039 | 1,802 | 1,490 | 2,090 | N/A |
9/30/2020 | 8,303 | 2,086 | 1,700 | 2,312 | N/A |
6/30/2020 | 8,112 | 1,710 | 1,899 | 2,424 | N/A |
3/31/2020 | 7,584 | 1,526 | 1,294 | 1,839 | N/A |
12/31/2019 | 7,796 | 1,725 | 1,427 | 1,990 | N/A |
9/30/2019 | 7,652 | 1,687 | 1,152 | 1,834 | N/A |
6/30/2019 | 7,323 | 1,564 | 998 | 1,669 | N/A |
3/31/2019 | 6,799 | 1,498 | 877 | 1,557 | N/A |
12/31/2018 | 6,356 | 1,219 | 429 | 1,501 | N/A |
9/30/2018 | 5,832 | 1,304 | 361 | 1,241 | N/A |
6/30/2018 | 5,310 | 1,214 | N/A | 1,063 | N/A |
3/31/2018 | 4,942 | 970 | N/A | 954 | N/A |
12/31/2017 | 4,538 | 899 | N/A | 913 | N/A |
9/30/2017 | 4,234 | 874 | N/A | 772 | N/A |
6/30/2017 | 3,974 | 797 | N/A | 728 | N/A |
3/31/2017 | 3,701 | 734 | N/A | 770 | N/A |
12/31/2016 | 3,468 | 679 | N/A | 692 | N/A |
9/30/2016 | 3,318 | 649 | N/A | 778 | N/A |
6/30/2016 | 3,113 | 610 | N/A | 693 | N/A |
3/31/2016 | 2,938 | 569 | N/A | 509 | N/A |
12/31/2015 | 2,769 | 521 | N/A | 436 | N/A |
9/30/2015 | 2,419 | 520 | N/A | 374 | N/A |
6/30/2015 | 2,208 | 500 | N/A | 363 | N/A |
3/31/2015 | 1,934 | 458 | N/A | 324 | N/A |
12/31/2014 | 1,669 | 423 | N/A | 348 | N/A |
9/30/2014 | 1,578 | 405 | N/A | 277 | N/A |
6/30/2014 | 1,490 | 385 | N/A | 284 | N/A |
3/31/2014 | 1,375 | 362 | N/A | 330 | N/A |
12/31/2013 | 1,303 | 362 | N/A | 330 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei 300003 ( 42.4% per jaar) ligt boven de spaarquote ( 2.9% ).
Winst versus markt: De winst van 300003 ( 42.4% per jaar) zal naar verwachting sneller groeien dan de CN markt ( 25.8% per jaar).
Hoge groeiwinsten: De winst van 300003 zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van 300003 ( 19.4% per jaar) zal naar verwachting sneller groeien dan de markt CN ( 14.1% per jaar).
Hoge groei-inkomsten: De omzet van 300003 ( 19.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen 300003 zal naar verwachting over 3 jaar laag zijn ( 9.6 %).